• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

HEMOGENYX PHARMACEUTICALS PLC

Notes

No. Proposition For Against Abstain
1

TO RECEIVE AND ADOPT THE COMPANYS ANNUAL ACCOUNTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

2

TO APPROVE THE DIRECTORS REMUNERATION REPORT AS SET OUT IN THE 2024 ANNUAL REPORT AND ACCOUNTS, FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2024

3

TO RE-APPOINT AS DIRECTOR PETER REDMOND, WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF FOR RE-ELECTION

4

TO REAPPOINT PKF LITTLEJOHN LLP AS THE COMPANYS AUDITOR UNTIL THE GENERAL MEETING OF THE COMPANY

5

TO AUTHORISE THE AUDIT COMMITTEE TO DETERMINE THE LEVEL OF THE AUDITORS REMUNERATION

6

THAT, IN ACCORDANCE WITH SECTION551 OF THE COMPANIES ACT 2006 THE DIRECTORS BE GENERALLY AND UNCONDITIONALLY AUTHORISED TO ALLOT SHARES

7

THAT, CONDITIONAL ON THE PASSING OF RESOLUTION 6, THE DIRECTORS BE GENERALLY EMPOWERED TO ALLOT EQUITY SECURITIES

8

TO AUTHORISE THE DIRECTORS TO CALL A GENERAL MEETING OF THE COMPANY, OTHER THAN AN ANNUAL GENERAL MEETING, ON NOT LESS THAN 14 CLEAR DAYS NOTICE